 |
programs
PMC brings together thought leaders from every part of the healthcare industry — and other industries and institutions that have a stake in personalized medicine — to explore issues that may require new or revised policies.
| PMC has already engaged the following organizations in both private and public meetings: |
- The Food and Drug Administration
(CDER, CBER, CDRH, OIVD)
- Center for Medicare and Medicaid Services
- National Human Genome Research Institute
- The White House
- The Institute of Medicine
|
- The National Cancer Institute
- U.S. House Committee on Science
- The National Breast Cancer Coalition
- The Genetic Alliance
- The National Health Council
|
|
| |
| Upcoming Programs [ Past Programs 2008 | 2007 | 2006 | 2005 | 2004 | 2003 ]
|
| 2008 |
|
| |
|
| Past Programs |
|
| 2008 |
|
March 7, 2008 |
Personalized Medicine Coalition's Fourth Annual Keynote Luncheon
12:00 noon - 2:00 p.m.
Venue: National Press Club, Holeman Lounge
Washington, DC
View Event Details
|
January 17, 2008 |
PMC East Coast Reception
Organized by: Personalized Medicine Coalition
Venue: The Broad Institute of MIT and Harvard
Cambridge, MA
View Event Details
|
| 2007 |
|
December 10, 2007 |
PMC West Coast Reception
Organized by: Personalized Medicine Coalition
Venue: Four Seasons Silicon Valley at East Palo Alto
East Palo Alto, CA
View Event Details
|
September 18-19 |
21st Century Medicine: Personalized and Evidence-Based
Organized by: PMC and Georgetown University School of Nursing & Health Studies
Venue: Georgetown University Law Center
Washington, DC
View Event Details
|
March 23 |
PMC’s Third Annual Keynote Luncheon Address on the State of Personalized Medicine with The Honorable Michael O. Leavitt, Secretary of Health and Human Services
Organized by: Personalized Medicine Coalition
Venue: National Press Club
Washington, DC
View Event Details
View Briefing Materials |
| 2006 |
|
November 28-29 |
Personalized Medicine: A World of Opportunities Conference
Organized by: Harvard-Partners Center for Genetics and Genomics and The Harvard Business School
Venue: Harvard Medical School
Boston, MA
View presentations
View photos
|
October 19 |
The Business Models for Personalized Medicine
Marrying Molecular Diagnostics and Therapeutics
Organized by: PMC
Venue: UCSF Conference Center at Mission Bay
San Francisco, CA
View Event Details
|
August 17 |
Personalized Medicine and CNS Disorders: The Changing Landscape of Mental and Neurological Illness
Organized by: MIT
Venue: MIT Stata Center, Building 32 [MAP]
Cambridge, MA
View Event Summary and Presentations
|
March 6
|
PMC Luncheon Address
12:00 p.m. - 2:00 p.m.
National Press Club
Washington, D.C.
Featured Guest Speaker:
Andrew C. von Eschenbach, M.D.
Acting Commissioner, U.S. Food and Drug Administration
 View Video
|
| 2005 |
|
| |
Personalized Medicine Coalition's
West Coast Inaugural Dinner and Networking Event
| View Event Details |
Special Guest Speaker:
Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics, Harvard Medical School and Scientific Director, Harvard-Partners Center for Genetics and Genomics, Boston, MA
Hosted by:
Steven Burrill, Burrill & Company
Brook Byers, Kleiner, Perkins, Caufield & Byers
Michael Goldberg, MDV - Mohr, Davidow Venture
Venue:
Sharon Heights Golf and Country Club
Menlo Park, CA
(This dinner is by invitation only.) |
September 28 |
Congressional Briefing on Personalized Medicine and
Genetic Non-Discrimination
Washington, DC
| View Event Details |
Special Guest Speakers:
Newt Gingrich, Founder, Center for Health Transformation
Francis Collins, Director, National Human Genome Research Institute
Hosted by:
Representatives Judy Biggert (R-IL), Anna Eshoo (D-CA), Bob Ney (R-OH),
and Louise Slaughter (D-NY)
|
September 7 |
Public Attitudes Toward Genetics
Washington, DC
| | Read Summary of Event | |
| Close Summary of Event | |
Americans are extraordinarily favorable to the idea of using genomics to improve health care, with large majorities saying that they would like to see pharmacogenomic data used to improve drug safety and efficacy. But they are also very fearful of how genetic information may be used, according to Christy White of Cogent Research, who reported the results of her new survey of public attitudes toward genetics at a PMC seminar on the subject on September 7th.
According to White, 68 percent of those polled in a scientific survey say that they are "concerned about how personal genetic information would be stored and who would have access to that information." And almost one third say that their concern would prevent them from having a genetic test. Americans, she found in large numbers, do not trust insurance companies, with 69 percent agreeing with the statement that insurance companies would deny coverage for drugs people need if a genetic profile indicates a low chance of their responding. This poses a potentially serious problem for the introduction of pharmacogenomics into the future of medicine. Almost three quarters of her sample said that the government should protect the privacy of information.
Resting on the assumption that policymakers, business executives, and healthcare providers must pay attention to public opinion when new technologies are introduced, the PMC convened the seminar to begin its consideration of the subject in an effort to better serve those interested in helping advance personalized medicine in the public sphere. Attended by almost 100 people from the diverse sectors that comprise our membership, our panel included Kathy Hudson, Ph.D., of the Genetics and Public Policy Center and Sharon Terry of the Genetic Alliance, who also shared their concerns, based upon earlier surveys they have done, regarding how the public is absorbing the challenges of new genetic information. The panel was moderated by Marcia Kean of Feinstein Kean Healthcare.
|
| View Event Details |
Introduction by:
Alan E. Guttmacher, M.D., Deputy Director, National Human Genome
Research Institute
Panelists:
Kathy Hudson, Ph.D., Director, Genetics and Public Policy Center,
Johns Hopkins University
Sharon Terry, President and CEO, Genetic Alliance
Christy White, Principal and Founder, Cogent Research
Moderator:
Marcia Kean, CEO, Feinstein Kean Healthcare
|
May 23 |
PMC Members' Luncheon
"Advancing Towards the Era of Personalized Medicine: FDA's
Pharmacogenomics Initiative"
| View Event Details |
Janet Woodcock, M.D., Acting Deputy Commissioner for Operations,
U.S. Food and Drug Administration
|
March 29 |
Personalized Medicine Coalition Reception
| View Event Details |
Eric Lander, Ph.D., Director, Broad Institute
Raju Kucherlapati, Ph.D., Scientific Director, Harvard-Partners Center for
Genetics and Genomics
Mark Levin, CEO, Millennium Pharmaceuticals
|
February 10 |
Personalized Medicine – How the Human Genome Era Will Usher in a Healthcare Revolution
Francis S. Collins, M.D., Ph.D., Director, National Human Genome Research Institute, National Institutes of Health
 View Presentation
View Video
|
| 2004 |
|
|
Personalized Medicine and Regulatory Approval
Janet Woodcock, Director, Center for Drug Evaluation and Research
Larry Lesko, Director, Office of Clinical Pharmacology and Biopharmaceutics, CDER, FDA
Shiew Mei Huang, Deputy Director, Office of Science, CDRH, FDA
Steven Gutman, Supervisory Medical Officer, CDRH, FDA
Jerry Collins, Director, Laboratory of Clinical Pharmacology, Office of Pharmaceutical Science, CDER , FDA
|
|
The Vision of Personalized Medicine in the Medical Provider Community
Patrick Terry, Co-Founder, Genomic Health, Inc.
Joseph D. McInerney, Executive Director, NCHPEG (National Coalition for Health Professional Education in Genetics)
Norman B. Kahn, Jr., Vice President, Science and Education, Director of Medical Education, CME, and Science Policy, American Academy of Family Medicine
Lawrence O'Connor, Director of Genetics Programs, American Medical Association
Howard Levy, Practicing Internist, Johns Hopkins Medicine
Dale Halsey Lea, Foundation for Blood Research, Assistant Director, Southern Maine Genetic Services
|
|
Reimbursement for Clinical Lab Tests: A Threat to Innovation in Personalized Medicine
Dee Simons, Director, Public Health Policy, Roche Diagnostics
David Sundwall, President, American Clinical Laboratory Association
G. Gregg Raab, Raab & Assocaites, consultant in reimbursement and regulation of innovative technology
|
|
The Story of Herceptin, HER2 and FISH -- A Case Study in the First Personalized Medicine
Cheryl Madsen, Senior Manager, Regulatory Affairs, Genentech
View Presentation
Paul Landuaer, Director, Health Policy and Payment for Abbott Molecular Diagnostics/Abbott Labs
View Presentation
|
| 2003 |
|
|
Kick-off
Rachel Levinson, Asst. Director for Life Sciences, Office of Science &Technology Policy
Geoff Ginsburg, Vice President, Molecular Medicine & Research Strategy, Millennium Pharmaceuticals (now Director of the Duke Institute for Genome Sciences & Policy Center)
|
|
The Future of Personalized Medicine and Case Examples
Alan Guttmacher, Deputy Director, National Human Genome Research Institute
Walter Moore, Vice President, Government Affairs, Genentech, Inc.
|
|
The Future of Personalized Medicine, Diagnostics Roundtable
Mark Levin, Chairman and CEO, Millennium Pharmaceuticals
Patrick Terry, Co-founder and Director of Consumer Advocacy, Genomic Health
Steve Seelig, Vice President, Research and Development, Vysis, Inc.
|
|
Electronic Data Management
Ned McCulloch, Senior Program Manager, IBM
Donald Rucker, Vice President and Chief Medical Officer, Siemens
|
|
Cost-Effectiveness and Personalized Medicine
Sean Tunis, Director of the Office of Clinical Standards and Quality and Chief Medical Officer at CMS
Stan Finkelstein, Senior Research Scientist, MIT Sloan School of Management & Co-Director, Program on the Pharmaceutical Industry
Bryan Luce, Senior Research Leader & Chairman of the Board, MEDTAP International
Kevin Schulman, Professor of Medicine and Business Administration, Director, The Center for Clinical and Genetic Economics, & Vice-Chair for Business Affairs, Department of Medicine, Duke Clinical Research Institute
David Veenstra, Assistant Professor, Pharmaceutical Outcomes Research and Policy Program (PORPP) and Institute for Public Health Genetics, University of Washington
|
|
Patent Protection and Personalized Medicine
Stephen A. Merrill, Executive Director, Board on Science, Technology, and Economic Policy (STEP), National Academy of Sciences
John Doll, Director, Technology Center, U.S. Patent and Trademark Office
Bruce Artim, Chief Counsel, U.S. Senate Committee on the Judiciary |
|
|
